| Year |
Citation |
Score |
| 2023 |
Stepanov AV, Xie J, Zhu Q, Shen Z, Su W, Kuai L, Soll R, Rader C, Shaver G, Douthit L, Zhang D, Kalinin R, Fu X, Zhao Y, Qin T, et al. Control of the antitumour activity and specificity of CAR T cells via organic adapters covalently tethering the CAR to tumour cells. Nature Biomedical Engineering. PMID 37798444 DOI: 10.1038/s41551-023-01102-5 |
0.529 |
|
| 2023 |
Chang J, Rader C, Peng H. A mammalian cell display platform based on scFab transposition. Antibody Therapeutics. 6: 157-169. PMID 37492588 DOI: 10.1093/abt/tbad009 |
0.385 |
|
| 2023 |
Cyr MG, Wilson HD, Spierling AL, Chang J, Peng H, Steinberger P, Rader C. Concerted antibody and antigen discovery by differential whole-cell phage display selections and multi-omic target deconvolution. Journal of Molecular Biology. 168085. PMID 37019174 DOI: 10.1016/j.jmb.2023.168085 |
0.388 |
|
| 2023 |
Steele AD, Kiefer AF, Hwang D, Yang D, Teijaro CN, Adhikari A, Rader C, Shen B. Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody-Drug Conjugates Revealing Key Insights into Structure-Activity Relationships. Journal of Medicinal Chemistry. PMID 36599039 DOI: 10.1021/acs.jmedchem.2c01771 |
0.37 |
|
| 2022 |
Cyr MG, Mhibik M, Qi J, Peng H, Chang J, Gaglione EM, Eik D, Herrick J, Venables T, Novick SJ, Courouble VV, Griffin PR, Wiestner A, Rader C. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia. Journal For Immunotherapy of Cancer. 10. PMID 36442911 DOI: 10.1136/jitc-2022-004850 |
0.348 |
|
| 2022 |
Hwang D, Nilchan N, Park H, Roy RN, Roush WR, Rader C. Sculpting a Uniquely Reactive Cysteine Residue for Site-Specific Antibody Conjugation. Bioconjugate Chemistry. PMID 35584359 DOI: 10.1021/acs.bioconjchem.2c00146 |
0.332 |
|
| 2021 |
Hu EY, Do P, Goswami S, Nunes J, Chiang CL, Elgamal S, Ventura AM, Cheney C, Zapolnik K, Williams E, Mani R, Frissora F, Mo X, Waldmeier L, Beerli RR, ... ... Rader C, et al. The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1+ leukemia. Blood Advances. 5: 3152-3162. PMID 34424320 DOI: 10.1182/bloodadvances.2020003276 |
0.369 |
|
| 2021 |
Lin CW, Zheng T, Grande G, Nanna AR, Rader C, Lerner RA. A new immunochemical strategy for triple-negative breast cancer therapy. Scientific Reports. 11: 14875. PMID 34290315 DOI: 10.1038/s41598-021-94230-4 |
0.529 |
|
| 2021 |
Goydel RS, Rader C. Antibody-based cancer therapy. Oncogene. 40: 3655-3664. PMID 33947958 DOI: 10.1038/s41388-021-01811-8 |
0.787 |
|
| 2021 |
Nilchan N, Alburger JM, Roush WR, Rader C. An Engineered Arginine Residue of Unusual pH-Sensitive Reactivity Facilitates Site-Selective Antibody Conjugation. Biochemistry. PMID 33754696 DOI: 10.1021/acs.biochem.0c00955 |
0.355 |
|
| 2021 |
Kovalovsky D, Yoon JH, Cyr MG, Simon S, Voynova E, Rader C, Wiestner A, Alejo J, Pittaluga S, Gress RE. Siglec-6 is a target for chimeric antigen receptor T-cell treatment of chronic lymphocytic leukemia. Leukemia. PMID 33633313 DOI: 10.1038/s41375-021-01188-3 |
0.301 |
|
| 2021 |
Bhoj VG, Li L, Parvathaneni K, Zhang Z, Kacir S, Arhontoulis D, Zhou K, McGettigan-Croce B, Nunez-Cruz S, Gulendran G, Boesteanu AC, Johnson L, Feldman MD, Radaelli E, Mansfield K, ... ... Rader C, et al. Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. Molecular Therapy Oncolytics. 20: 387-398. PMID 33614919 DOI: 10.1016/j.omto.2021.01.012 |
0.787 |
|
| 2020 |
Qi J, Rader C. Redirecting cytotoxic T cells with chemically programmed antibodies. Bioorganic & Medicinal Chemistry. 28: 115834. PMID 33166926 DOI: 10.1016/j.bmc.2020.115834 |
0.302 |
|
| 2020 |
Adhikari A, Teijaro C, Yan X, Chang CY, Gui C, Liu YC, Crnovcic I, Yang D, Annaval T, Rader C, Shen B. Characterization of TnmH as an O-Methyltransferase Revealing In-sights into Tiancimycin Biosynthesis and Enabling a Biocatalytic Strategy to Prepare Antibody-Tiancimycin Conjugates. Journal of Medicinal Chemistry. PMID 32658465 DOI: 10.1021/Acs.Jmedchem.0C00799 |
0.439 |
|
| 2020 |
Hwang D, Rader C. Site-Specific Antibody-Drug Conjugates in Triple Variable Domain Fab Format. Biomolecules. 10. PMID 32422893 DOI: 10.3390/biom10050764 |
0.374 |
|
| 2020 |
Nanna AR, Kel'in AV, Theile C, Pierson JM, Voo ZX, Garg A, Nair JK, Maier MA, Fitzgerald K, Rader C. Generation and validation of structurally defined antibody-siRNA conjugates. Nucleic Acids Research. PMID 32347936 DOI: 10.1093/Nar/Gkaa286 |
0.472 |
|
| 2020 |
Qi J, Tsuji K, Hymel D, Burke TR, Hudecek M, Rader C, Peng H. Chemically programmable and switchable CAR-T therapy. Angewandte Chemie (International Ed. in English). PMID 32329959 DOI: 10.1002/Anie.202005432 |
0.477 |
|
| 2020 |
Goydel RS, Weber J, Peng H, Qi J, Soden J, Freeth J, Park H, Rader C. Affinity maturation, humanization, and co-crystallization of a rabbit anti-human ROR2 monoclonal antibody for therapeutic applications. The Journal of Biological Chemistry. PMID 32193207 DOI: 10.1074/Jbc.Ra120.012791 |
0.795 |
|
| 2019 |
Rader C. Bispecific antibodies in cancer immunotherapy. Current Opinion in Biotechnology. 65: 9-16. PMID 31841859 DOI: 10.1016/J.Copbio.2019.11.020 |
0.387 |
|
| 2019 |
Hwang D, Tsuji K, Park H, Burke TR, Rader C. Site-Specific Lysine Arylation as an Alternative Bioconjugation Strategy for Chemically Programmed Antibodies and Antibody-Drug Conjugates. Bioconjugate Chemistry. PMID 31675216 DOI: 10.2210/Pdb6U85/Pdb |
0.454 |
|
| 2019 |
Qi J, Hymel D, Nelson CG, Burke TR, Rader C. Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1. Frontiers in Immunology. 10: 1994. PMID 31497024 DOI: 10.3389/Fimmu.2019.01994 |
0.387 |
|
| 2019 |
Rader C, Wiestner A. Six-packed antibodies punch better. Haematologica. 104: 1696-1699. PMID 31473607 DOI: 10.3324/Haematol.2019.224196 |
0.389 |
|
| 2019 |
Nanna AR, Rader C. Engineering Dual Variable Domains for the Generation of Site-Specific Antibody-Drug Conjugates. Methods in Molecular Biology (Clifton, N.J.). 2033: 39-52. PMID 31332746 DOI: 10.1007/978-1-4939-9654-4_4 |
0.416 |
|
| 2019 |
Hwang D, Nilchan N, Nanna AR, Li X, Cameron MD, Roush WR, Park H, Rader C. Site-Selective Antibody Functionalization via Orthogonally Reactive Arginine and Lysine Residues. Cell Chemical Biology. PMID 31231031 DOI: 10.2210/Pdb6Dzr/Pdb |
0.416 |
|
| 2019 |
Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, Smythe KS, Dudakov JA, Pierce RH, Rader C, Riddell SR. Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting. Cancer Cell. 35: 489-503.e8. PMID 30889382 DOI: 10.1016/J.Ccell.2019.02.003 |
0.346 |
|
| 2019 |
Rader C. "One, if by land, and two, if by sea": bispecific antibodies join the revolution. Methods (San Diego, Calif.). 154: 1-2. PMID 30683271 DOI: 10.1016/J.Ymeth.2018.12.004 |
0.379 |
|
| 2019 |
Goswami S, Chiang C, Zapolnik K, Xie Z, Lee JL, Baskar S, Rader C, Byrd JC, Phelps MA, Bhatnagar B, Muthusamy N. ROR1 Targeted Immunoliposomal Delivery of OSU-2S Show Selective Cytotoxicity in t(1;19) Translocated B-ALL Blood. 134: 3798-3798. DOI: 10.1182/Blood-2019-128828 |
0.33 |
|
| 2019 |
Mhibik M, Gaglione EM, Blackburn A, Keyvanfar K, Sun C, Ahn IE, Baptista MJ, Qi J, Rader C, Wiestner A. A CD19/CD3 Bispecific Antibody Induces Superior T Cell Responses Against Chronic Lymphocytic Leukemia When Combined with Ibrutinib Blood. 134: 2861-2861. DOI: 10.1182/Blood-2019-126186 |
0.321 |
|
| 2019 |
Specht J, Lee S, Turtle C, Berger C, Balakrishnan A, Srivastava S, Viollet V, Veatch J, Gooley T, Mullane E, Chaney C, Rader C, Pierce R, Gottardo R, Maloney D, et al. Abstract P2-09-13: A phase I study of adoptive immunotherapy for ROR1+ advanced triple negative breast cancer (TNBC) with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR) Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P2-09-13 |
0.358 |
|
| 2019 |
Hu E, Do P, Mani R, Frissora F, Pearson R, Lozanski G, Peng H, Waldmeier L, Beerli R, Rader C, Grawunder U, Byrd J, Muthusamy N. Abstract 1541: Evaluation of ROR1 targeted antibody drug conjugate in ROR1 positive leukemia Cancer Research. 79: 1541-1541. DOI: 10.1158/1538-7445.Am2019-1541 |
0.443 |
|
| 2018 |
Rydzek J, Nerreter T, Peng H, Jutz S, Leitner J, Steinberger P, Einsele H, Rader C, Hudecek M. Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 30573301 DOI: 10.1016/J.Ymthe.2018.11.015 |
0.374 |
|
| 2018 |
Mage RG, Esteves PJ, Rader C. Rabbit models of human diseases for diagnostics and therapeutics development. Developmental and Comparative Immunology. PMID 30339876 DOI: 10.1016/J.Dci.2018.10.003 |
0.349 |
|
| 2018 |
Wilson HD, Li X, Peng H, Rader C. A Sortase a Programmable Phage Display Format for Improved Panning of Fab Antibody Libraries. Journal of Molecular Biology. PMID 30213726 DOI: 10.1016/J.Jmb.2018.09.003 |
0.478 |
|
| 2018 |
Qi J, Chen SS, Chiorazzi N, Rader C. An IgG1-like bispecific antibody targeting CD52 and CD20 for the treatment of B-cell malignancies. Methods (San Diego, Calif.). PMID 30145356 DOI: 10.1016/J.Ymeth.2018.08.008 |
0.421 |
|
| 2018 |
Chang J, Peng H, Shaffer BC, Baskar S, Wecken IC, Cyr MG, Martinez GJ, Soden J, Freeth J, Wiestner A, Rader C. Siglec-6 on chronic lymphocytic leukemia cells is a target for post-allogeneic hematopoietic stem cell transplantation antibodies. Cancer Immunology Research. PMID 29980538 DOI: 10.1158/2326-6066.Cir-18-0102 |
0.485 |
|
| 2018 |
Qi J, Li X, Peng H, Cook EM, Dadashian EL, Wiestner A, Park H, Rader C. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1. Proceedings of the National Academy of Sciences of the United States of America. PMID 29844189 DOI: 10.1073/Pnas.1719905115 |
0.46 |
|
| 2018 |
Specht JM, Lee S, Turtle CJ, Berger C, Baladrishnan A, Srivastava S, Voillet V, Veatch J, Gooley T, Mullane E, Chaney C, Rader C, Pierce RH, Gottardo R, Maloney DG, et al. Abstract CT131: A phase I study of adoptive immunotherapy for advanced ROR1+ malignancies with defined subsets of autologous T cells expressing a ROR1-specific chimeric antigen receptor (ROR1-CAR) Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct131 |
0.358 |
|
| 2017 |
Yan X, Chen JJ, Adhikari A, Yang D, Crnovcic I, Wang N, Chang CY, Rader C, Shen B. Genome Mining of Micromonospora yangpuensis DSM 45577 as a Producer of an Anthraquinone-Fused Enediyne. Organic Letters. PMID 29086572 DOI: 10.1021/Acs.Orglett.7B03120 |
0.323 |
|
| 2017 |
Nanna AR, Li X, Walseng E, Pedzisa L, Goydel RS, Hymel D, Burke TR, Roush WR, Rader C. Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates. Nature Communications. 8: 1112. PMID 29062027 DOI: 10.1038/S41467-017-01257-1 |
0.777 |
|
| 2017 |
Zhuang X, Watts NR, Palmer IW, Kaufman JD, Dearborn AD, Trenbeath JL, Eren E, Steven AC, Rader C, Wingfield PT. Chimeric Rabbit/Human Fab Antibodies Against the Hepatitis B e-antigen and Their Potential Applications in Assay, Characterization and Therapy. The Journal of Biological Chemistry. PMID 28842495 DOI: 10.1074/Jbc.M117.802272 |
0.385 |
|
| 2017 |
Peng H, Nerreter T, Chang J, Qi J, Li X, Karunadharma P, Martinez G, Fallahi M, Soden J, Freeth J, Beerli RR, Grawunder U, Hudecek M, Rader C. Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility. Journal of Molecular Biology. PMID 28818634 DOI: 10.1016/J.Jmb.2017.08.003 |
0.487 |
|
| 2017 |
Weber J, Peng H, Rader C. From rabbit antibody repertoires to rabbit monoclonal antibodies. Experimental & Molecular Medicine. 49: e305. PMID 28336958 DOI: 10.1038/Emm.2017.23 |
0.458 |
|
| 2017 |
Li X, Nelson CG, Nair RR, Hazlehurst L, Moroni T, Martinez-Acedo P, Nanna AR, Hymel D, Burke TR, Rader C. Stable and Potent Selenomab-Drug Conjugates. Cell Chemical Biology. PMID 28330604 DOI: 10.1016/J.Chembiol.2017.02.012 |
0.425 |
|
| 2017 |
Li X, Rader C. Utilization of Selenocysteine for Site-Specific Antibody Conjugation. Methods in Molecular Biology (Clifton, N.J.). 1575: 145-164. PMID 28255878 DOI: 10.1007/978-1-4939-6857-2_8 |
0.439 |
|
| 2017 |
Chiang C, Goswami S, Mani R, Frissora F, Xie Z, Huang X, Baskar S, Rader C, Phelps MA, Marcucci G, Byrd JC, Lee JL, Muthusamy N. Tumor Antigen ROR1 Targeted Delivery of MiR-29b in Chronic Lymphocytic Leukemia Induces Epigenetic Reprograming Resulting in Cell Cycle Arrest Blood. 130: 4981-4981. DOI: 10.1182/Blood.V130.Suppl_1.4981.4981 |
0.303 |
|
| 2017 |
Hickey SC, Nanna AR, Nguyen HN, Ofori L, Rader C, Rood MK, Wanner J, Werner DS. Abstract 5153: Tunable Drug Conjugates: a differentiated drug conjugate (DC) platform Cancer Research. 77: 5153-5153. DOI: 10.1158/1538-7445.Am2017-5153 |
0.391 |
|
| 2017 |
Moreadith RW, Viegas TX, Bentley MD, Harris JM, Fang Z, Yoon K, Dizman B, Weimer R, Rae BP, Li X, Rader C, Standaert D, Olanow W. Clinical development of a poly(2-oxazoline) (POZ) polymer therapeutic for the treatment of Parkinson’s disease – Proof of concept of POZ as a versatile polymer platform for drug development in multiple therapeutic indications European Polymer Journal. 88: 524-552. DOI: 10.1016/J.Eurpolymj.2016.09.052 |
0.33 |
|
| 2016 |
Patterson JT, Wilson HD, Asano S, Nilchan N, Fuller RP, Roush WR, Rader C, Barbas CF. Human Serum Albumin Domain I Fusion Protein for Antibody Conjugation. Bioconjugate Chemistry. PMID 27666414 DOI: 10.1021/Acs.Bioconjchem.6B00432 |
0.732 |
|
| 2016 |
Gnaim S, Scomparin A, Li X, Baran PS, Rader C, Satchi-Fainaro R, Shabat D. Tagging the Untaggable: A Difluoroalkyl-Sulfinate Ketone-Based Reagent for Direct C-H Functionalization of Bioactive Heteroarenes. Bioconjugate Chemistry. PMID 27494153 DOI: 10.1021/Acs.Bioconjchem.6B00382 |
0.565 |
|
| 2016 |
Walseng E, Nelson CG, Qi J, Nanna AR, Roush WR, Goswami RK, Sinha SC, Burke TR, Rader C. Chemically programmed bispecific antibodies in diabody format. The Journal of Biological Chemistry. PMID 27445334 DOI: 10.1074/Jbc.M116.745588 |
0.459 |
|
| 2016 |
Pedzisa L, Li X, Rader C, Roush WR. Assessment of reagents for selenocysteine conjugation and the stability of selenocysteine adducts. Organic & Biomolecular Chemistry. PMID 27184239 DOI: 10.1039/C6Ob00775A |
0.415 |
|
| 2016 |
Li W, Li X, Huang T, Teng Q, Crnovcic I, Rader C, Shen B. Engineered production of cancer targeting peptide (CTP)-containing C-1027 in Streptomyces globisporus and biological evaluation. Bioorganic & Medicinal Chemistry. PMID 27094150 DOI: 10.1016/J.Bmc.2016.04.017 |
0.335 |
|
| 2016 |
Sarkar M, Liu Y, Qi J, Peng H, Morimoto J, Rader C, Chiorazzi N, Kodadek T. Targeting stereotyped B cell receptors from chronic lymphocytic leukemia patients with synthetic antigen surrogates. The Journal of Biological Chemistry. PMID 26851280 DOI: 10.1074/Jbc.M115.701656 |
0.393 |
|
| 2016 |
Bhoj VG, Nunez-Cruz S, Zhou K, Arhontoulis D, Feldman M, Mansfield K, Peng H, Rader C, Siegel DL, Milone MC. Abstract 2295: GDNF family receptor alpha 4 (GFRa4)-targeted adoptive T-cell immunotherapy for medullary thyroid carcinoma Cancer Research. 76: 2295-2295. DOI: 10.1158/1538-7445.Am2016-2295 |
0.453 |
|
| 2016 |
Carstens EJ, Skarzynski M, Butera V, Lindorfer M, Vire B, Farooqui M, Rader C, Taylor R, Wiestner A. Abstract 1490: Potentiating immunotherapy by targeting complement deposited on cancer cell surfaces Cancer Research. 76: 1490-1490. DOI: 10.1158/1538-7445.Am2016-1490 |
0.338 |
|
| 2015 |
Huang X, Park H, Greene J, Pao J, Mulvey E, Zhou SX, Albert CM, Moy F, Sachdev D, Yee D, Rader C, Hamby CV, Loeb DM, Cairo MS, Zhou X. IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas. Plos One. 10: e0133152. PMID 26173023 DOI: 10.1371/Journal.Pone.0133152 |
0.363 |
|
| 2015 |
Li X, Patterson JT, Sarkar M, Pedzisa L, Kodadek T, Roush WR, Rader C. Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues. Bioconjugate Chemistry. PMID 26161903 DOI: 10.1021/Acs.Bioconjchem.5B00244 |
0.711 |
|
| 2015 |
Mani R, Chiang CL, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Klisovic R, Phelps MA, Chen CS, Lee RJ, Byrd JC, Baiocchi R, Lee LJ, Muthusamy N. ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo. Experimental Hematology. PMID 25937048 DOI: 10.1016/J.Exphem.2015.04.008 |
0.424 |
|
| 2015 |
Chinthalapudi K, Patil DN, Rangarajan ES, Rader C, Izard T. Lipid-directed vinculin dimerization. Biochemistry. 54: 2758-68. PMID 25880222 DOI: 10.1021/Acs.Biochem.5B00015 |
0.339 |
|
| 2015 |
Rader C. Chemical biology: How to minimalize antibodies. Nature. 518: 38-9. PMID 25652990 DOI: 10.1038/518038A |
0.451 |
|
| 2015 |
Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, Kosasih PL, Rader C, Riddell SR. Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunology Research. 3: 206-16. PMID 25355068 DOI: 10.1158/2326-6066.Cir-14-0163 |
0.385 |
|
| 2015 |
Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunology Research. 3: 125-35. PMID 25212991 DOI: 10.1158/2326-6066.Cir-14-0127 |
0.381 |
|
| 2015 |
Skarzynski M, Lindorfer M, Butera V, Vire B, Farooqui M, Rader C, Taylor R, Wiestner A. Monoclonal antibodies targeting cell surface deposited complement fragment C3d potentiate cancer immunotherapy and eliminate antigen loss variants Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P372 |
0.412 |
|
| 2015 |
Mani R, Chiang C, Frissora FW, Yan R, Mo X, Baskar S, Rader C, Phelps M, Chen C, Lee R, Byrd J, Baiocchi R, Lee LJ, Muthusamy N. Abstract 4406: ROR1 targeted delivery of OSU-2S, a non-immunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle cell lymphomain-vitroandin-vivo Cancer Research. 75: 4406-4406. DOI: 10.1158/1538-7445.Am2015-4406 |
0.413 |
|
| 2015 |
Park H, Huang X, Greene J, Pao J, Mulvey E, Zhou SX, Sachdev D, Yee D, Rader C, Albert CM, Hamby C, Loeb D, Cairo MS, Zhou X. IGF1R- and ROR1-Specific Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas Biology of Blood and Marrow Transplantation. 21: S52-S53. DOI: 10.1016/J.Bbmt.2014.11.686 |
0.352 |
|
| 2014 |
Sarkar M, Liu Y, Morimoto J, Peng H, Aquino C, Rader C, Chiorazzi N, Kodadek T. Recognition of antigen-specific B-cell receptors from chronic lymphocytic leukemia patients by synthetic antigen surrogates. Chemistry & Biology. 21: 1670-9. PMID 25467125 DOI: 10.1016/J.Chembiol.2014.10.010 |
0.401 |
|
| 2014 |
Vire B, Skarzynski M, Thomas JD, Nelson CG, David A, Aue G, Burke TR, Rader C, Wiestner A. Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia. Cancer Research. 74: 7510-20. PMID 25344228 DOI: 10.1158/0008-5472.Can-14-2030 |
0.434 |
|
| 2014 |
Rader C, Segal DJ, Shabat D. Carlos F. Barbas III (1964-2014): Visionary at the interface of chemistry and biology. Acs Chemical Biology. 9: 1645-6. PMID 25123302 DOI: 10.1021/Cb5005993 |
0.596 |
|
| 2014 |
Patterson JT, Asano S, Li X, Rader C, Barbas CF. Improving the serum stability of site-specific antibody conjugates with sulfone linkers. Bioconjugate Chemistry. 25: 1402-7. PMID 25099687 DOI: 10.1021/Bc500276M |
0.712 |
|
| 2014 |
Grönwall C, Charles ED, Dustin LB, Rader C, Silverman GJ. Selection of apoptotic cell specific human antibodies from adult bone marrow. Plos One. 9: e95999. PMID 24760047 DOI: 10.1371/Journal.Pone.0095999 |
0.483 |
|
| 2014 |
Rader C. Chemically programmed antibodies. Trends in Biotechnology. 32: 186-97. PMID 24630478 DOI: 10.1016/J.Tibtech.2014.02.003 |
0.42 |
|
| 2014 |
Li X, Yang J, Rader C. Antibody conjugation via one and two C-terminal selenocysteines. Methods (San Diego, Calif.). 65: 133-8. PMID 23756202 DOI: 10.1016/J.Ymeth.2013.05.023 |
0.454 |
|
| 2014 |
Berger SC, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paskiewicz P, Kosasih P, Rader C, Riddell S. Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P3 |
0.407 |
|
| 2014 |
Huang X, Greene J, Pao J, Mulvey E, Zhou SX, Sachdev D, Yee D, Rader C, Albert CM, Park H, Chu Y, Hamby C, Loeb D, Cairo MS, Zhou X. Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Poor Risk Sarcomas Biology of Blood and Marrow Transplantation. 20: S184-S185. DOI: 10.1016/J.Bbmt.2013.12.302 |
0.336 |
|
| 2013 |
Stoeckli ET, Kilinc D, Kunz B, Kunz S, Lee GU, Martines E, Rader C, Suter D. Analysis of cell-cell contact mediated by Ig superfamily cell adhesion molecules. Current Protocols in Cell Biology / Editorial Board, Juan S. Bonifacino ... [Et Al.]. 61: 9.5.1-9.5.85. PMID 24510806 DOI: 10.1002/0471143030.Cb0905S61 |
0.737 |
|
| 2013 |
Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 3153-64. PMID 23620405 DOI: 10.1158/1078-0432.Ccr-13-0330 |
0.419 |
|
| 2013 |
Skarzynski M, Vire B, Thomas JD, Nelson CG, David A, Aue G, Burke TR, Rader C, Wiestner A. Targeting the Fcμ-receptor in chronic lymphocytic leukemia with a novel IgM-derived antibody-drug conjugate Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P136 |
0.444 |
|
| 2013 |
Mani R, Mao Y, Frissora FW, Chiang C, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Baskar S, Rader C, Phelps MA, Lee RJ, Chen C, et al. Tumor Antigen ROR1 Targeted Delivery Of FTY720 Derivative OSU-2S Prolongs Survival In ROR1 Engineered Mouse Model Of Chronic Lymphocytic Leukemia Blood. 122: 4168-4168. DOI: 10.1182/Blood.V122.21.4168.4168 |
0.381 |
|
| 2012 |
Dave H, Anver MR, Butcher DO, Brown P, Khan J, Wayne AS, Baskar S, Rader C. Restricted cell surface expression of receptor tyrosine kinase ROR1 in pediatric B-lineage acute lymphoblastic leukemia suggests targetability with therapeutic monoclonal antibodies. Plos One. 7: e52655. PMID 23285131 DOI: 10.1371/Journal.Pone.0052655 |
0.403 |
|
| 2012 |
Thomas JD, Cui H, North PJ, Hofer T, Rader C, Burke TR. Application of strain-promoted azide-alkyne cycloaddition and tetrazine ligation to targeted Fc-drug conjugates. Bioconjugate Chemistry. 23: 2007-13. PMID 22988967 DOI: 10.1021/Bc300052U |
0.428 |
|
| 2012 |
Cui H, Thomas JD, Burke TR, Rader C. Chemically programmed bispecific antibodies that recruit and activate T cells. The Journal of Biological Chemistry. 287: 28206-14. PMID 22761439 DOI: 10.1074/Jbc.M112.384594 |
0.448 |
|
| 2012 |
Yang J, Rader C. Cloning, expression, and purification of monoclonal antibodies in scFv-Fc format. Methods in Molecular Biology (Clifton, N.J.). 901: 209-32. PMID 22723104 DOI: 10.1007/978-1-61779-931-0_14 |
0.428 |
|
| 2012 |
Rader C. Selection of human Fab libraries by phage display. Methods in Molecular Biology (Clifton, N.J.). 901: 81-99. PMID 22723095 DOI: 10.1007/978-1-61779-931-0_5 |
0.431 |
|
| 2012 |
Rader C. Generation of human Fab libraries for phage display. Methods in Molecular Biology (Clifton, N.J.). 901: 53-79. PMID 22723094 DOI: 10.1007/978-1-61779-931-0_4 |
0.428 |
|
| 2012 |
Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C. Targeting malignant B cells with an immunotoxin against ROR1. Mabs. 4: 349-61. PMID 22531447 DOI: 10.4161/Mabs.19870 |
0.409 |
|
| 2012 |
Shaffer BC, Leitner J, Wiestner A, Bishop MR, Pavletic SZ, Gress RE, Steinberger P, Baskar S, Rader C. Generation of a Platform for Identification of CLL Specific Cell Surface Proteins Targeted by Anti-Tumor Antibodies in Patient Sera After Allogeneic Hematopoietic Cell Transplantion Blood. 120: 1349-1349. DOI: 10.1182/Blood.V120.21.1349.1349 |
0.48 |
|
| 2011 |
Andris-Widhopf J, Steinberger P, Fuller R, Rader C, Barbas CF. Generation of human Fab antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences. Cold Spring Harbor Protocols. 2011. PMID 21880817 DOI: 10.1101/pdb.prot065565 |
0.311 |
|
| 2011 |
Andris-Widhopf J, Steinberger P, Fuller R, Rader C, Barbas CF. Generation of human scFv antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences. Cold Spring Harbor Protocols. 2011. PMID 21880816 DOI: 10.1101/Pdb.Prot065573 |
0.404 |
|
| 2011 |
Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C. Therapeutic potential and challenges of targeting receptor tyrosine kinase ROR1 with monoclonal antibodies in B-cell malignancies. Plos One. 6: e21018. PMID 21698301 DOI: 10.1371/Journal.Pone.0021018 |
0.449 |
|
| 2011 |
Rader C. DARTs take aim at BiTEs. Blood. 117: 4403-4. PMID 21527536 DOI: 10.1182/Blood-2011-02-337691 |
0.339 |
|
| 2011 |
Bagnara D, Kaufman MS, Calissano C, Marsilio S, Patten PE, Simone R, Chum P, Yan XJ, Allen SL, Kolitz JE, Baskar S, Rader C, Mellstedt H, Rabbani H, Lee A, et al. A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. Blood. 117: 5463-72. PMID 21385850 DOI: 10.1182/Blood-2010-12-324210 |
0.351 |
|
| 2011 |
Pérez-Galán P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti EG, Chapman CM, Mo CC, Stennett LS, Rader C, Liu P, Raghavachari N, Stetler-Stevenson M, Yuan C, Pittaluga S, Maric I, et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood. 117: 542-52. PMID 20956803 DOI: 10.1182/Blood-2010-02-269514 |
0.308 |
|
| 2011 |
Ho M, Feng M, Fisher RJ, Rader C, Pastan I. A novel high-affinity human monoclonal antibody to mesothelin. International Journal of Cancer. Journal International Du Cancer. 128: 2020-30. PMID 20635390 DOI: 10.1002/Ijc.25557 |
0.435 |
|
| 2011 |
Vire B, David A, Thomas JD, Burke TR, Rader C, Wiestner A. Fcμ-Receptor (FcμR; TOSO/FAIM3) Mediated Internalization of Antibody-Drug Conjugates: A Novel Approach to Selectively Target Chronic Lymphocytic Leukemia Cells Blood. 118: 734-734. DOI: 10.1182/Blood.V118.21.734.734 |
0.394 |
|
| 2011 |
Hudecek M, Lupo-Stanghellini M, Kosasih P, Bet J, Paszkiewicz P, Maloney DG, Jensen MC, Rader C, Riddell SR. Naïve CD4+ T Cells Modified to Express a ROR1-Specific CAR Mediate Anti-Tumor Activity and Provide Superior Help to CD8+ ROR1-CAR T Cells Blood. 118: 643-643. DOI: 10.1182/Blood.V118.21.643.643 |
0.339 |
|
| 2011 |
Dave H, Baskar S, Khan J, Wayne A, Rader C. Abstract 2578: ROR1: A novel target for pre-B acute lymphoblastic leukemia and neuroblastoma Cancer Research. 71: 2578-2578. DOI: 10.1158/1538-7445.Am2011-2578 |
0.386 |
|
| 2011 |
Hudecek M, Lupo-Stanghellini M, Yang J, Kosasih P, Paszkiewicz P, Bet J, Maloney DG, Jensen MC, Rader C, Riddell SR. 5.53 The Anti-Tumor Reactivity of ROR1-CAR Modified T Cells Depends on the Targeted Epitope, CAR-Affinity and Design of the CAR Extracellular Domain Clinical Lymphoma Myeloma and Leukemia. 11: S280-S281. DOI: 10.1016/J.Clml.2011.09.207 |
0.389 |
|
| 2011 |
Yang J, Baskar S, Kwong KY, Kennedy MG, Wiestner A, Rader C. 5.1 Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in CLL Clinical Lymphoma Myeloma and Leukemia. 11: S243. DOI: 10.1016/J.Clml.2011.09.155 |
0.396 |
|
| 2010 |
Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 116: 4532-41. PMID 20702778 DOI: 10.1182/Blood-2010-05-283309 |
0.393 |
|
| 2010 |
Beerli RR, Rader C. Mining human antibody repertoires. Mabs. 2: 365-78. PMID 20505349 DOI: 10.4161/Mabs.12187 |
0.451 |
|
| 2010 |
Stahl SJ, Watts NR, Rader C, DiMattia MA, Mage RG, Palmer I, Kaufman JD, Grimes JM, Stuart DI, Steven AC, Wingfield PT. Generation and characterization of a chimeric rabbit/human Fab for co-crystallization of HIV-1 Rev. Journal of Molecular Biology. 397: 697-708. PMID 20138059 DOI: 10.1016/J.Jmb.2010.01.061 |
0.409 |
|
| 2010 |
Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, ... ... Rader C, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 115: 2619-29. PMID 19965642 DOI: 10.1182/Blood-2009-09-242438 |
0.369 |
|
| 2010 |
Lee DW, Kochenderfer JN, Rader C, Orentas RJ, Mackall CL. Novel Antigen-Specific Expansion of T Cells Transduced with a CD19 Chimeric Antigen Receptor Blood. 116: 3262-3262. DOI: 10.1182/Blood.V116.21.3262.3262 |
0.368 |
|
| 2009 |
Hofer T, Skeffington LR, Chapman CM, Rader C. Molecularly defined antibody conjugation through a selenocysteine interface. Biochemistry. 48: 12047-57. PMID 19894757 DOI: 10.1021/Bi901744T |
0.481 |
|
| 2009 |
Baskar S, Suschak JM, Samija I, Srinivasan R, Childs RW, Pavletic SZ, Bishop MR, Rader C. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. Blood. 114: 4494-502. PMID 19667400 DOI: 10.1182/Blood-2009-05-222786 |
0.445 |
|
| 2009 |
Robak LA, Venkatesh K, Lee H, Raiker SJ, Duan Y, Lee-Osbourne J, Hofer T, Mage RG, Rader C, Giger RJ. Molecular basis of the interactions of the Nogo-66 receptor and its homolog NgR2 with myelin-associated glycoprotein: development of NgROMNI-Fc, a novel antagonist of CNS myelin inhibition. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 5768-83. PMID 19420245 DOI: 10.1523/Jneurosci.4935-08.2009 |
0.641 |
|
| 2009 |
Derfuss T, Parikh K, Velhin S, Braun M, Mathey E, Krumbholz M, Kümpfel T, Moldenhauer A, Rader C, Sonderegger P, Pöllmann W, Tiefenthaller C, Bauer J, Lassmann H, Wekerle H, et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proceedings of the National Academy of Sciences of the United States of America. 106: 8302-7. PMID 19416878 DOI: 10.1073/Pnas.0901496106 |
0.546 |
|
| 2009 |
Rader C. Generation and selection of rabbit antibody libraries by phage display. Methods in Molecular Biology (Clifton, N.J.). 525: 101-28, xiv. PMID 19252834 DOI: 10.1007/978-1-59745-554-1_5 |
0.454 |
|
| 2009 |
Rader C. Overview on concepts and applications of Fab antibody fragments. Current Protocols in Protein Science / Editorial Board, John E. Coligan ... [Et Al.]. Unit 6.9. PMID 19235140 DOI: 10.1002/0471140864.Ps0609S55 |
0.337 |
|
| 2009 |
Kwong KY, Rader C. E. coli expression and purification of Fab antibody fragments. Current Protocols in Protein Science / Editorial Board, John E. Coligan ... [Et Al.]. Unit 6.10. PMID 19235139 DOI: 10.1002/0471140864.Ps0610S55 |
0.405 |
|
| 2008 |
Thomas JD, Hofer T, Rader C, Burke TR. Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates. Bioorganic & Medicinal Chemistry Letters. 18: 5785-8. PMID 18922692 DOI: 10.1016/J.Bmcl.2008.09.078 |
0.476 |
|
| 2008 |
Giger RJ, Venkatesh K, Chivatakarn O, Raiker SJ, Robak L, Hofer T, Lee H, Rader C. Mechanisms of CNS myelin inhibition: evidence for distinct and neuronal cell type specific receptor systems. Restorative Neurology and Neuroscience. 26: 97-115. PMID 18820405 |
0.589 |
|
| 2008 |
Kwong KY, Baskar S, Zhang H, Mackall CL, Rader C. Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. Journal of Molecular Biology. 384: 1143-56. PMID 18809410 DOI: 10.1016/J.Jmb.2008.09.008 |
0.454 |
|
| 2008 |
Hofer T, Thomas JD, Burke TR, Rader C. An engineered selenocysteine defines a unique class of antibody derivatives. Proceedings of the National Academy of Sciences of the United States of America. 105: 12451-6. PMID 18719095 DOI: 10.1073/Pnas.0800800105 |
0.446 |
|
| 2008 |
Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, Staudt LM, Wilson WH, Wiestner A, Rader C. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 396-404. PMID 18223214 DOI: 10.1158/1078-0432.Ccr-07-1823 |
0.338 |
|
| 2008 |
Giger RJ, Vogt L, Zuellig RA, Rader C, Henehan-Beatty A, Wolfer DP, Sonderegger P. The Gene of Chicken Axonin-1 European Journal of Biochemistry. 227: 617-628. DOI: 10.1111/J.1432-1033.1995.0617P.X |
0.7 |
|
| 2007 |
Abraham S, Guo F, Li LS, Rader C, Liu C, Barbas CF, Lerner RA, Sinha SC. Synthesis of the next-generation therapeutic antibodies that combine cell targeting and antibody-catalyzed prodrug activation. Proceedings of the National Academy of Sciences of the United States of America. 104: 5584-9. PMID 17372220 DOI: 10.1073/Pnas.0700223104 |
0.579 |
|
| 2007 |
Hofer T, Tangkeangsirisin W, Kennedy MG, Mage RG, Raiker SJ, Venkatesh K, Lee H, Giger RJ, Rader C. Chimeric rabbit/human Fab and IgG specific for members of the Nogo-66 receptor family selected for species cross-reactivity with an improved phage display vector. Journal of Immunological Methods. 318: 75-87. PMID 17140598 DOI: 10.1016/J.Jim.2006.10.007 |
0.68 |
|
| 2006 |
Jendreyko N, Rader C, Barbas CF, Gaedicke G. Simultaneous, phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody enhances antiangiogenic effects in vivo. Klinische Pã¤Diatrie. 218: 143-51. PMID 16688670 DOI: 10.1055/S-2006-933415 |
0.319 |
|
| 2006 |
Popkov M, Rader C, Gonzalez B, Sinha SC, Barbas CF. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector. International Journal of Cancer. Journal International Du Cancer. 119: 1194-207. PMID 16570283 DOI: 10.1002/Ijc.21924 |
0.472 |
|
| 2006 |
Rader C, Barbas CF. Synthetic antibodies prey on B cells Blood. 108: 2889-2890. DOI: 10.1182/Blood-2006-08-041327 |
0.425 |
|
| 2005 |
Nathan S, Rader C, Barbas CF. Neutralization of Burkholderia pseudomallei protease by Fabs generated through phage display. Bioscience, Biotechnology, and Biochemistry. 69: 2302-11. PMID 16377887 DOI: 10.1271/Bbb.69.2302 |
0.601 |
|
| 2005 |
Venkatesh K, Chivatakarn O, Lee H, Joshi PS, Kantor DB, Newman BA, Mage R, Rader C, Giger RJ. The Nogo-66 receptor homolog NgR2 is a sialic acid-dependent receptor selective for myelin-associated glycoprotein. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 808-22. PMID 15673660 DOI: 10.1523/Jneurosci.4464-04.2005 |
0.622 |
|
| 2004 |
Li LS, Rader C, Matsushita M, Das S, Barbas CF, Lerner RA, Sinha SC. Chemical adaptor immunotherapy: design, synthesis, and evaluation of novel integrin-targeting devices. Journal of Medicinal Chemistry. 47: 5630-40. PMID 15509162 DOI: 10.1021/Jm049666K |
0.585 |
|
| 2004 |
Sinha SC, Li LS, Watanabe S, Kaltgrad E, Tanaka F, Rader C, Lerner RA, Barbas CF. Aldolase antibody activation of prodrugs of potent aldehyde-containing cytotoxics for selective chemotherapy. Chemistry (Weinheim An Der Bergstrasse, Germany). 10: 5467-72. PMID 15378729 DOI: 10.1002/Chem.200400419 |
0.677 |
|
| 2004 |
Popkov M, Rader C, Barbas CF. Isolation of human prostate cancer cell reactive antibodies using phage display technology. Journal of Immunological Methods. 291: 137-51. PMID 15345312 DOI: 10.1016/J.Jim.2004.05.004 |
0.447 |
|
| 2004 |
Popkov M, Jendreyko N, Gonzalez-Sapienza G, Mage RG, Rader C, Barbas CF. Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library. Journal of Immunological Methods. 288: 149-64. PMID 15183093 DOI: 10.1016/J.Jim.2004.03.005 |
0.452 |
|
| 2004 |
Gopin A, Rader C, Shabat D. New chemical adaptor unit designed to release a drug from a tumor targeting device by enzymatic triggering. Bioorganic & Medicinal Chemistry. 12: 1853-8. PMID 15051054 DOI: 10.1016/J.Bmc.2004.01.041 |
0.561 |
|
| 2004 |
Sinha SC, Li LS, Miller GP, Dutta S, Rader C, Lerner RA. Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab. Proceedings of the National Academy of Sciences of the United States of America. 101: 3095-9. PMID 14981258 DOI: 10.1073/Pnas.0307319101 |
0.551 |
|
| 2004 |
Chung J, Rader C, Popkov M, Hur YM, Kim HK, Lee YJ, Barbas CF. Integrin alphaIIbbeta3-specific synthetic human monoclonal antibodies and HCDR3 peptides that potently inhibit platelet aggregation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 18: 361-3. PMID 14688205 DOI: 10.1096/Fj.03-0586Fje |
0.572 |
|
| 2004 |
Jendreyko N, Popkov M, Rader C, Barbas CF, Gaedicke G. Simultaneous Silencing of Two Independent Signaling Pathways Essential for Angiogenesis Using Bispecific, Tetravalent Intra-Diabodies. Blood. 104: 5284-5284. DOI: 10.1182/Blood.V104.11.5284.5284 |
0.314 |
|
| 2003 |
Rader C, Turner JM, Heine A, Shabat D, Sinha SC, Wilson IA, Lerner RA, Barbas CF. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy. Journal of Molecular Biology. 332: 889-99. PMID 12972259 DOI: 10.1016/S0022-2836(03)00992-6 |
0.709 |
|
| 2003 |
Jendreyko N, Popkov M, Beerli RR, Chung J, McGavern DB, Rader C, Barbas CF. Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. The Journal of Biological Chemistry. 278: 47812-9. PMID 12947084 DOI: 10.1074/Jbc.M307002200 |
0.562 |
|
| 2003 |
Rader C, Sinha SC, Popkov M, Lerner RA, Barbas CF. Chemically programmed monoclonal antibodies for cancer therapy: adaptor immunotherapy based on a covalent antibody catalyst. Proceedings of the National Academy of Sciences of the United States of America. 100: 5396-400. PMID 12702756 DOI: 10.1073/Pnas.0931308100 |
0.589 |
|
| 2003 |
Gopin A, Pessah N, Shamis M, Rader C, Shabat D. A chemical adaptor system designed to link a tumor-targeting device with a prodrug and an enzymatic trigger. Angewandte Chemie (International Ed. in English). 42: 327-32. PMID 12548691 DOI: 10.1002/Anie.200390108 |
0.54 |
|
| 2003 |
Popkov M, Mage RG, Alexander CB, Thundivalappil S, Barbas CF, Rader C. Rabbit immune repertoires as sources for therapeutic monoclonal antibodies: the impact of kappa allotype-correlated variation in cysteine content on antibody libraries selected by phage display. Journal of Molecular Biology. 325: 325-35. PMID 12488098 DOI: 10.1016/S0022-2836(02)01232-9 |
0.462 |
|
| 2002 |
Rader C, Popkov M, Neves JA, Barbas CF. Integrin alpha(v)beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 16: 2000-2. PMID 12397091 DOI: 10.1096/Fj.02-0281Fje |
0.431 |
|
| 2002 |
Kunz B, Lierheimer R, Rader C, Spirig M, Ziegler U, Sonderegger P. Axonin-1/TAG-1 mediates cell-cell adhesion by a cis-assisted trans-interaction. The Journal of Biological Chemistry. 277: 4551-7. PMID 11733523 DOI: 10.1074/Jbc.M109779200 |
0.585 |
|
| 2001 |
Sonderegger P, Kunz S, Rader C, Suter DM, Stoeckli ET. Analysis of cell-cell contact mediated by Ig superfamily cell adhesion molecules. Current Protocols in Cell Biology / Editorial Board, Juan S. Bonifacino ... [Et Al.]. Unit 9.5. PMID 18228394 DOI: 10.1002/0471143030.Cb0905S11 |
0.764 |
|
| 2001 |
Plagge A, Sendtner-Voelderndorff L, Sirim P, Freigang J, Rader C, Sonderegger P, Brümmendorf T. The contactin-related protein FAR-2 defines purkinje cell clusters and labels subpopulations of climbing fibers in the developing cerebellum. Molecular and Cellular Neurosciences. 18: 91-107. PMID 11461156 DOI: 10.1006/Mcne.2001.1006 |
0.551 |
|
| 2001 |
Shabat D, Lode HN, Pertl U, Reisfeld RA, Rader C, Lerner RA, Barbas CF. In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 98: 7528-33. PMID 11404472 DOI: 10.1073/Pnas.131187998 |
0.709 |
|
| 2001 |
Rader C. Antibody libraries in drug and target discovery. Drug Discovery Today. 6: 36-43. PMID 11165171 DOI: 10.1016/S1359-6446(00)01595-6 |
0.46 |
|
| 2001 |
Rader C. Antibody libraries in drug and target discovery Drug Discovery Today. 6: 36-43. DOI: 10.1016/S1359-6446(00)01595-6 |
0.302 |
|
| 2000 |
Barbas CF, Rader C, Segal DJ, List B, Turner JM. From catalytic asymmetric synthesis to the transcriptional regulation of genes: in vivo and in vitro evolution of proteins. Advances in Protein Chemistry. 55: 317-66. PMID 11050938 DOI: 10.1016/S0065-3233(01)55008-1 |
0.605 |
|
| 2000 |
Andris-Widhopf J, Rader C, Steinberger P, Fuller R, Barbas CF. Methods for the generation of chicken monoclonal antibody fragments by phage display. Journal of Immunological Methods. 242: 159-81. PMID 10986398 DOI: 10.1016/S0022-1759(00)00221-0 |
0.434 |
|
| 2000 |
Steinberger P, Sutton JK, Rader C, Elia M, Barbas CF. Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. The Journal of Biological Chemistry. 275: 36073-8. PMID 10969070 DOI: 10.1074/Jbc.M002765200 |
0.451 |
|
| 2000 |
Rader C, List B. Catalytic antibodies as magic bullets. Chemistry (Weinheim An Der Bergstrasse, Germany). 6: 2091-5. PMID 10926212 DOI: 10.1002/1521-3765(20000616)6:12<2091::Aid-Chem2091>3.0.Co;2-S |
0.534 |
|
| 2000 |
Fitzli D, Stoeckli ET, Kunz S, Siribour K, Rader C, Kunz B, Kozlov SV, Buchstaller A, Lane RP, Suter DM, Dreyer WJ, Sonderegger P. A direct interaction of axonin-1 with NgCAM-related cell adhesion molecule (NrCAM) results in guidance, but not growth of commissural axons. The Journal of Cell Biology. 149: 951-68. PMID 10811834 DOI: 10.1083/Jcb.149.4.951 |
0.756 |
|
| 2000 |
Rader C, Ritter G, Nathan S, Elia M, Gout I, Jungbluth AA, Cohen LS, Welt S, Old LJ, Barbas CF. The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies. The Journal of Biological Chemistry. 275: 13668-76. PMID 10788485 DOI: 10.1074/Jbc.275.18.13668 |
0.63 |
|
| 2000 |
Karlstrom A, Zhong G, Rader C, Larsen NA, Heine A, Fuller R, List B, Tanaka F, Wilson IA, Barbas CF, Lerner RA. Using antibody catalysis to study the outcome of multiple evolutionary trials of a chemical task. Proceedings of the National Academy of Sciences of the United States of America. 97: 3878-83. PMID 10760259 DOI: 10.1073/Pnas.97.8.3878 |
0.718 |
|
| 1999 |
Shabat D, Rader C, List B, Lerner RA, Barbas CF. Multiple event activation of a generic prodrug trigger by antibody catalysis. Proceedings of the National Academy of Sciences of the United States of America. 96: 6925-30. PMID 10359815 DOI: 10.1073/Pnas.96.12.6925 |
0.737 |
|
| 1998 |
Sonderegger P, Kunz S, Rader C, Buchstaller A, Berger P, Vogt L, Kozlov SV, Ziegler U, Kunz B, Fitzli D, Stoeckli ET. Discrete clusters of axonin-1 and NgCAM at neuronal contact sites: facts and speculations on the regulation of axonal fasciculation. Progress in Brain Research. 117: 93-104. PMID 9932403 DOI: 10.1016/S0079-6123(08)64010-8 |
0.688 |
|
| 1998 |
Kunz S, Spirig M, Ginsburg C, Buchstaller A, Berger P, Lanz R, Rader C, Vogt L, Kunz B, Sonderegger P. Neurite fasciculation mediated by complexes of axonin-1 and Ng cell adhesion molecule. The Journal of Cell Biology. 143: 1673-90. PMID 9852159 DOI: 10.1083/Jcb.143.6.1673 |
0.565 |
|
| 1998 |
Rader C, Cheresh DA, Barbas CF. A phage display approach for rapid antibody humanization: designed combinatorial V gene libraries. Proceedings of the National Academy of Sciences of the United States of America. 95: 8910-5. PMID 9671778 DOI: 10.1073/Pnas.95.15.8910 |
0.46 |
|
| 1997 |
Rader C, Barbas CF. Phage display of combinatorial antibody libraries. Current Opinion in Biotechnology. 8: 503-8. PMID 9265732 DOI: 10.1016/S0958-1669(97)80075-4 |
0.452 |
|
| 1996 |
Buchstaller A, Kunz S, Berger P, Kunz B, Ziegler U, Rader C, Sonderegger P. Cell adhesion molecules NgCAM and axonin-1 form heterodimers in the neuronal membrane and cooperate in neurite outgrowth promotion. The Journal of Cell Biology. 135: 1593-607. PMID 8978825 DOI: 10.1083/Jcb.135.6.1593 |
0.588 |
|
| 1996 |
Rader C, Kunz B, Lierheimer R, Giger RJ, Berger P, Tittmann P, Gross H, Sonderegger P. Implications for the domain arrangement of axonin-1 derived from the mapping of its NgCAM binding site. The Embo Journal. 15: 2056-68. PMID 8641271 DOI: 10.1002/J.1460-2075.1996.Tb00559.X |
0.718 |
|
| 1995 |
Giger RJ, Vogt L, Zuellig RA, Rader C, Henehan-Beatty A, Wolfer DP, Sonderegger P. The gene of chicken axonin-1. Complete structure and analysis of the promoter. European Journal of Biochemistry / Febs. 227: 617-28. PMID 7867620 DOI: 10.1111/J.1432-1033.1995.Tb20181.X |
0.699 |
|
| 1993 |
Hasler TH, Rader C, Stoeckli ET, Zuellig RA, Sonderegger P. cDNA cloning, structural features, and eucaryotic expression of human TAG-1/axonin-1. European Journal of Biochemistry / Febs. 211: 329-39. PMID 8425542 DOI: 10.1111/J.1432-1033.1993.Tb19902.X |
0.729 |
|
| 1993 |
Rader C, Stoeckli ET, Ziegler U, Osterwalder T, Kunz B, Sonderegger P. Cell-cell adhesion by homophilic interaction of the neuronal recognition molecule axonin-1. European Journal of Biochemistry / Febs. 215: 133-41. PMID 8344273 DOI: 10.1111/J.1432-1033.1993.Tb18015.X |
0.711 |
|
| 1992 |
Zuellig RA, Rader C, Schroeder A, Kalousek MB, Von Bohlen und Halbach F, Osterwalder T, Inan C, Stoeckli ET, Affolter HU, Fritz A. The axonally secreted cell adhesion molecule, axonin-1. Primary structure, immunoglobulin-like and fibronectin-type-III-like domains and glycosyl-phosphatidylinositol anchorage. European Journal of Biochemistry / Febs. 204: 453-63. PMID 1311675 DOI: 10.1111/J.1432-1033.1992.Tb16655.X |
0.612 |
|
| Show low-probability matches. |